Palisade Bio
PALI

$3.83

4.73%

Market Cap: $4.54M

About: Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Employees: 9

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

6.85% less ownership

Funds ownership: 10.05% [Q1] → 3.2% (-6.85%) [Q2]

53% less funds holding

Funds holding: 15 [Q1] → 7 (-8) [Q2]

64% less capital invested

Capital invested by funds: $371K [Q1] → $135K (-$236K) [Q2]

80% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 10

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 5

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for PALI.

See Analyst Rankings

Financial journalist opinion

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition of Matter coverage beyond 2042 PALI-2108 is in development to treat patients with active moderate-to-severely active Ulcerative Colitis (UC) PALI-1908 is in development to treat patients with active fibro stenotic Crohn's Disease (CD) Carlsbad, CA, July 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that European Patent Office (EPO) has issued a decision to grant notice for patent number 4,157,853 titled, “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors.” Based on the intention to grant notice, the Company expects the EPO to issue a patent July 31, 2024.

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) before year end Carlsbad, CA, July 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the successful completion of the first Good Manufacturing Practice (GMP) batch of its drug substance PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC. The GMP manufacturing was conducted in partnership with Eurofins, a contract development and manufacturing organization.

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, June 26, 2024 at 4:00 PM ET. As part of the event, J.D.

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

– Collaboration advancing Palisade Bio's precision medicine approach through access to cutting-edge expertise and tools in bioinformatics

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

Zacks Investment Research

Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now

Palisade Bio (PALI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end Carlsbad, CA, June 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for patent application number 3,174,137 titled, “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors.” This patent covers the composition of PALI-2108, the Company's orally administered, locally acting colon-specific Phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by Ulcerative Colitis (UC).

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

See News Rankings